The company maintains a clean capital structure with a 0.00 debt-to-equity ratio, though liquidity remains constrained with a current ratio of 0.17 as of 2024Q4.
| Metric | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Current Assets | 0 | 18.57K | 25.88K | 37.84K | 764.5K | 0 | 32.74K | 36.72K | 45.27K | 2.62M | 2.49M | 324.75K | 278.58K | 2.3M | 81.69M | 86.99M | 70.98M | 74.48M | 100.46M | 77.37M | 58.91M | 207.73K | 140.33K | 225.01K | 606.19K | 126.37K | 74.53K | 300K | 400K | 1.2M |
| Cash & Short-Term Investments | 0 | 0 | 0 | 0 | 710.7K | 617.8K | 0 | 0 | 1.09M | 2.18M | 2.46M | 0 | 0 | 0 | 59.63K | 57.74K | 277.09K | 2.55M | 2.03M | 2.84M | 93K | 5.08K | 3.32K | 13.04K | 431.95K | 18.44K | 67.78K | 100K | 100K | 100K |
| Cash Only | 0 | 0 | 0 | 0 | 710.7K | 617.8K | 0 | 0 | 1.09M | 2.18M | 2.46M | 0 | 0 | 0 | 59.63K | 57.74K | 277.09K | 2.55M | 2.03M | 2.84M | 93K | 5.08K | 3.32K | 13.04K | 431.95K | 18.44K | 67.78K | 100K | 100K | 100K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 9.68K | 14.2K | 17.23K | 30.7K | 29.3K | 32.74K | 33.71K | 45.27K | 45.87K | 33.38K | 324.75K | 144.68K | 2.3M | 23.3M | 32.56M | 16.87M | 2.83M | 10.5M | 174.11K | 1.15M | 156.39K | 137.01K | 211.98K | 174.24K | 107.93K | 6.75K | 200K | 300K | 1.1M |
| Days Sales Outstanding | - | 1.66 | 0.15 | -17.8 | -4.28 | -3.81 | -103.91 | -13.4 | -16.33 | 9.12 | -1.64 | -29.24 | -4.57 | -399.01 | 6.66K | 7.53K | 3.65K | 586.55 | 2.05K | 42.75 | 312.56 | 46.85 | 15.8 | 28.64 | 83.86 | 52.82 | 4.28 | 243.33 | 219 | 143.39 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 301.53K | 363.63K | 454.41K | 426.83K | 255.83K | 171K | 191.86K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 168.67 | 182.4 | 235.31 | 301.89 | 196.25 | 110.32 | 52.99 | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 8.89K | 0 | 0 | 0 | -647.1K | 0 | 357K | 1.09M | 2.57M | 2.46M | 215.34K | 1.24M | -2.3M | 23.29M | 32.51M | 10.91M | 337.48K | 12.76M | 7.22M | 230.63K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 46.01M | 36.61M | 34.84M | 30.22M | 24.22M | 15.67M | 13.97M | 17.24M | 18.14M | 17.97M | 18.38M | 44.48M | 45.99M | 54.03M | 4.04M | 4.21M | 4.21M | 2.35M | 2.1M | 795.96K | 653.02K | 55.1M | 47.7M | 40.91M | 42.55M | 49.04M | 35.23M | 400K | 400K | 400K |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4M | 4.17M | 4.17M | 2.31M | 2.06M | 763.8K | 620.87K | 290.57K | 303.37K | 338.88K | 276.12K | 321.3K | 366.27K | 400K | 400K | 400K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.32x | 0.38x | 0.40x | 0.76x | 0.91x | 1.95x | 2.16x | 4.19x | 10.43x | 7.97x | 2.75x | 2.32x | 1.57x | 0.75x | 1.25x | 7.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 46M | 36.61M | 34.84M | 30.22M | 24.22M | 15.67M | 13.97M | 17.24M | 18.14M | 17.97M | 18.38M | 44.48M | 45.99M | 54.03M | 55.8M | 53.88M | 63.84M | 68.34M | 74.92M | 66.97M | 57.25M | 54.81M | 47.4M | 40.57M | 42.27M | 48.72M | 34.87M | 0 | 0 | 0 |
| Other Non-Current Assets | 9.86K | 0 | 0 | 0 | 0 | 0 | 0 | -17.24M | -18.14M | -17.97M | -18.38M | -44.48M | -45.99M | 0 | -60.33M | -62.84M | -74.43M | -76.37M | -90.61M | -82.22M | -57.21M | -55.1M | -47.7M | -40.91M | -42.55M | -49.04M | -35.23M | -400K | -400K | -400K |
| Total Assets | 46.01M | 36.63M | 34.87M | 30.26M | 24.98M | 16.55M | 14.2M | 17.63M | 19.31M | 20.62M | 20.89M | 46.05M | 47.39M | 56.33M | 85.72M | 91.2M | 75.19M | 76.82M | 102.56M | 78.17M | 59.57M | 55.93M | 48.3M | 41.57M | 43.54M | 49.58M | 35.85M | 44.1M | 41.3M | 37.3M |
| Asset Turnover | 0.01x | 0.06x | 0.99x | -0.01x | -0.10x | -0.17x | -0.01x | -0.05x | -0.05x | 0.09x | -0.36x | -0.09x | -0.24x | -0.04x | 0.01x | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x | 0.07x | 0.06x | 0.02x | 0.02x | 0.02x | 0.01x | 0.01x | 0.08x |
| Asset Growth % | 25.6% | 5.06% | 15.23% | 21.13% | 50.92% | 16.56% | -19.43% | -8.72% | -6.37% | -1.29% | -54.63% | -2.84% | -15.86% | -34.29% | -6% | 21.29% | -2.13% | -25.09% | 31.21% | 31.23% | 6.5% | 15.79% | 16.18% | -4.52% | -12.17% | 38.3% | -18.72% | 6.78% | 10.72% | -1.06% |
| Total Current Liabilities | 122.59K | 110.33K | 103.1K | 62.44K | 806.42K | 707K | 78.75K | 72.5K | 75K | 7.82K | 9.14K | 15.9K | 27.76K | 0 | 49.26M | 43.9M | 27.21M | 32.97M | 47.21M | 32.53M | 20.82M | 89.16K | 183.05K | 112.48K | 52.85K | 42.43K | 127.34K | 100K | 200K | 100K |
| Accounts Payable | 0 | 110.33K | 103.1K | 62.44K | 87.4K | 80K | 78.75K | 72.5K | 75K | 7.82K | 9.14K | 15.9K | 27.76K | 0 | 525.17K | 436.54K | 533.63K | 604.42K | 498.21K | 412.97K | 512.02K | 89.16K | 183.05K | 112.48K | 52.85K | 42.43K | 127.34K | 100K | 200K | 100K |
| Days Payables Outstanding | - | - | 212.52 | 20.96 | 31.85 | 42.54 | 78.29 | 98.56 | 136.82 | 10.31 | 10.59 | - | - | - | 293.77 | 218.98 | 276.33 | 427.5 | 382.18 | 266.43 | 141.41 | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 715.8K | 627K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.02M | -2.18M | -2.44M | 0 | 0 | 0 | 38.67K | 51.92K | 46.9K | 33.35K | 7.42K | 2.75K | 90.47K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 122.59K | 0 | 0 | 0 | 3.23K | 0 | 0 | -72.5K | -75K | -7.82K | -9.14K | -15.9K | -27.76K | 4.43M | -650.93K | -3.48M | -1.52M | -3.28M | -505.63K | -415.72K | -602.49K | -89.16K | -183.05K | -112.48K | -52.85K | -42.43K | -127.34K | -100K | -200K | -100K |
| Current Ratio | - | 0.17x | 0.25x | 0.61x | 0.95x | - | 0.42x | 0.51x | 0.60x | 335.00x | 272.35x | 20.43x | 10.04x | - | 1.66x | 1.98x | 2.61x | 2.26x | 2.13x | 2.38x | 2.83x | 2.33x | 0.77x | 2.00x | 11.47x | 2.98x | 0.59x | 3.00x | 2.00x | 12.00x |
| Quick Ratio | - | 0.17x | 0.25x | 0.61x | 0.95x | - | 0.42x | 0.51x | 0.60x | 335.00x | 272.35x | 20.43x | 10.04x | - | 1.65x | 1.97x | 2.59x | 2.25x | 2.12x | 2.37x | 2.82x | 2.33x | 0.77x | 2.00x | 11.47x | 2.98x | 0.59x | 3.00x | 2.00x | 12.00x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.53K | 7.49K | 3.61K | 460.94 | 1.86K | -113.36 | 224.14 | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 122.59K | 729.97K | 755.66K | 1.23M | 3.02M | 170.69K | 1.34M | 4.45M | 4.33M | 2.8M | 3.85M | 21.36M | 20.25M | 21.22M | 243.95K | 300.06K | 346.86K | 390.29K | 430.6K | 3.48M | 7.08M | 4.11M | 2.5M | 1.43M | 1M | 1.78M | 2.44M | 2.1M | 2.5M | 1.6M |
| Long-Term Debt | 112K | 729.97K | 755.66K | 1.23M | 3.02M | 170.69K | 1.34M | 4.45M | 4.33M | 2.8M | 3.85M | 21.36M | 20.25M | 10.68M | 14.05M | 27.39M | 11.16M | 13.48M | 3.78M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 10.6K | 0 | 0 | 0 | 0 | 0 | 0 | -4.45M | -4.33M | -2.8M | -3.85M | -21.36M | -20.25M | 4.43M | -14.05M | -27.39M | -11.16M | -13.48M | -3.78M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 122.59K | 840.3K | 858.76K | 1.29M | 3.83M | 877.69K | 1.44M | 4.56M | 5.55M | 5.28M | 6.47M | 21.47M | 21.02M | 21.22M | 49.51M | 44.2M | 27.56M | 33.36M | 47.64M | 32.53M | 20.82M | 16.05M | 11.88M | 8.03M | 8.21M | 10.9M | 6.57M | 8.8M | 8.4M | 5.5M |
| Total Debt | 112K | 729.97K | 755.66K | 1.23M | 3.02M | 170.69K | 1.34M | 4.45M | 4.33M | 2.8M | 3.85M | 21.36M | 20.25M | 10.68M | 14.05M | 27.39M | 11.16M | 13.48M | 3.78M | 3.48M | 7.08M | 4.11M | 2.5M | 1.43M | 1M | 1.78M | 2.44M | 2.1M | 2.5M | 1.6M |
| Net Debt | 112K | 729.97K | 755.66K | 1.23M | 2.31M | -447.11K | 1.34M | 4.45M | 3.25M | 617.87K | 1.39M | 21.36M | 20.25M | 10.68M | 13.99M | 27.33M | 10.88M | 10.94M | 1.75M | 644.23K | 6.99M | 4.11M | 2.5M | 1.42M | 568.05K | 1.76M | 2.38M | 2M | 2.4M | 1.5M |
| Debt / Equity | 0.00x | 0.02x | 0.02x | 0.04x | 0.14x | 0.01x | 0.11x | 0.34x | 0.32x | 0.18x | 0.27x | 0.87x | 0.77x | 0.30x | 0.39x | 0.58x | 0.23x | 0.31x | 0.07x | 0.08x | 0.18x | 0.10x | 0.07x | 0.04x | 0.03x | 0.05x | 0.08x | 0.06x | 0.08x | 0.05x |
| Debt / EBITDA | 0.01x | 0.35x | 0.90x | 0.20x | 0.55x | - | - | - | - | 1.91x | - | - | - | - | - | 3.17x | 1.50x | 0.68x | 0.31x | - | - | - | - | - | 2.34x | 1.46x | - | 2.10x | - | 2.29x |
| Net Debt / EBITDA | 0.01x | 0.35x | 0.90x | 0.20x | 0.42x | - | - | - | - | 0.42x | - | - | - | - | - | 3.16x | 1.46x | 0.55x | 0.14x | - | - | - | - | - | 1.33x | 1.44x | - | 2.00x | - | 2.14x |
| Interest Coverage | 575.44x | 7.30x | 6.72x | 72.47x | 243.19x | -204.98x | -3.45x | -10.05x | -41.21x | 39.31x | -49.06x | -19.16x | -40.13x | -12.02x | -1.72x | -4.66x | -1.57x | -1.56x | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 45.89M | 35.79M | 34.01M | 28.97M | 21.15M | 15.68M | 12.77M | 13.06M | 13.76M | 15.34M | 14.43M | 24.58M | 26.37M | 35.11M | 36.22M | 47M | 47.63M | 43.46M | 54.92M | 45.64M | 38.74M | 39.88M | 36.42M | 33.55M | 35.33M | 38.67M | 29.28M | 35.3M | 32.9M | 31.8M |
| Equity Growth % | 28.2% | 5.24% | 17.4% | 36.95% | 34.94% | 22.79% | -2.27% | -5.06% | -10.34% | 6.35% | -41.31% | -6.79% | -24.9% | -3.04% | -22.94% | -1.32% | 9.58% | -20.86% | 20.33% | 17.79% | -2.85% | 9.51% | 8.56% | -5.04% | -8.64% | 32.08% | -17.05% | 7.29% | 3.46% | -0.93% |
| Book Value per Share | 9.20 | 7.39 | 7.34 | 3.38 | 5.24 | 3.98 | 3.05 | 3.49 | 3.65 | 4.01 | 3.75 | 6.54 | 6.42 | 8.58 | 8.58 | 11.09 | 11.12 | 9.84 | 12.01 | 9.87 | 8.35 | 8.64 | 7.84 | 7.19 | 7.57 | 8.27 | 5.86 | 7.06 | 6.58 | 6.36 |
| Total Shareholders' Equity | 45.89M | 35.79M | 34.01M | 28.97M | 21.15M | 15.68M | 12.77M | 13.06M | 13.76M | 15.34M | 14.43M | 24.58M | 26.37M | 35.11M | 36.22M | 47M | 47.63M | 43.46M | 54.92M | 45.64M | 38.74M | 39.88M | 36.42M | 33.55M | 35.33M | 38.67M | 29.28M | 35.3M | 32.9M | 31.8M |
| Common Stock | 55.35K | 54.09K | 53.17K | 53.17K | 53.17K | 53.17K | 53.17K | 53.17K | 53.17K | 53.17K | 10.75M | 10.75M | 10.74M | 53.16K | 53.16K | 53.16K | 53.16K | 53.16K | 53.16K | 53.16K | 53.1K | 53.1K | 53.1K | 53.1K | 53.1K | 53.1K | 53.1K | 0 | 0 | 0 |
| Retained Earnings | 34.8M | 25.63M | 25.09M | 24.79M | 19.61M | 14.86M | 16.57M | 17.06M | 8.48M | 10.38M | 10.24M | 10.57M | 13M | 47.47M | 24.74M | 32.98M | 32.24M | 32.16M | 23.49M | 12.84M | 13.63M | 14.59M | 15.17M | 16.25M | 16.44M | 16.14M | 16.2M | 16.3M | 16.7M | 19.2M |
| Treasury Stock | -4.5M | -4.5M | -4.83M | -8.77M | -10.62M | -10.62M | -14.86M | -14.86M | -14.97M | -14.72M | -14.28M | -13.42M | -12.73M | -12.41M | -11.83M | -11.6M | -11.36M | -10.87M | -8.42M | -6.02M | -5.78M | -5.64M | -5.17M | -4.92M | -4.81M | -4.81M | -4.46M | -3.7M | 0 | 0 |
| Accumulated OCI | 34.8M | 0 | 0 | 24.79M | 19.61M | 14.86M | 0 | 17.06M | 0 | 0 | 0 | 0 | 0 | 0 | 12.57M | 14.89M | 16.02M | 11.46M | 29.21M | 28.38M | 20.54M | 0 | 0 | 0 | -1.95M | -919.41K | -861.16K | -800K | -700K | -700K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investment Portfolio Market Sensitivity
According to reported financial statements, Daxor's total assets grew from $16.7M in 2021Q2 to $46.0M by 2025Q4, a trend primarily driven by the appreciation of its internal investment portfolio rather than organic growth from its medical device operations or core diagnostic kit sales.
The trajectory of the balance sheet appears decoupled from the underlying medical business, as asset growth is largely a function of market-driven investment gains. Investors should monitor whether this asset accumulation provides a sustainable buffer or if it merely masks the lack of commercial traction in the BVA-100 platform.
Based on the most recent 2025Q4 filings, Daxor maintains a debt-to-equity ratio of 0.00, reflecting a debt-free capital structure that provides significant financial optionality despite the ongoing operational challenges and the lack of meaningful revenue generation from its primary medical instrumentation business segment.
The absence of debt suggests that the company is not reliant on external credit markets to fund its R&D or operational burn. This conservative leverage profile appears to be a strategic choice, allowing the firm to avoid interest rate exposure on its liabilities while it attempts to navigate the slow adoption of its diagnostic technology.
As indicated by historical balance sheet data, the company's current ratio has remained consistently low, fluctuating between 0.03 and 0.35 over the past several years, which suggests a structural reliance on liquidating investment assets to meet short-term operational obligations rather than relying on internal cash flow.
The consistently low current ratio implies that the company may face liquidity pressure if its investment portfolio experiences significant volatility or if market conditions prevent the timely liquidation of holdings. This warrants further investigation into the specific composition of current assets and the ease with which they can be converted to cash to support ongoing medical operations.
Based on the company's 1940 Act filing status, the balance sheet is fundamentally distorted by the inclusion of a large investment portfolio, which makes traditional metrics like return on assets or liquidity ratios potentially misleading indicators of the medical device business's actual health and commercial viability.
The reliance on investment gains to bolster the balance sheet creates a non-obvious risk where the company's financial stability is tied to market performance rather than product adoption. Analysts should be cautious, as a downturn in the utility or preferred stock sectors could rapidly erode the capital base that currently funds the company's research and development efforts.
Quick answers to the most common questions about buying DXR stock.
As of 2025, Daxor Corporation (DXR) had total assets of $46.0M including $0.0M in current assets.
Daxor Corporation (DXR) carries total debt of $0.1M, offset by $0.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Daxor Corporation (DXR) has total shareholders' equity (book value) of $45.9M ($9.20 book value per share). Book value represents the net worth of the company belonging to common stock holders.